somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-20. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
== Detection and treatment == Several detection methods can be used in order to determine the concentration of saxitoxin within an organism (be it shellfish or human), both in vivo and in vitro. The most commonly used in vivo method is the mouse bioassay, which provides quantitative and qualitative data in case of a (suspected) PSP neurotoxin exposure; in vitro receptor binding assays provide equivalent data, while being animal-friendly. PSP neurotoxins can also be detected by high-performance liquid chromatography (HPLC), amongst other forms of chromatography. Shellfish containing 80 or more micrograms of saxitoxin per 100g of edible shellfish tissue are deemed to be unsafe for human consumption. Currently, there is no antidote for PSP neurotoxins. Most PSP patients suffer only minor symptoms, these lasting until the toxin is eliminated from the body. With minor exposure, spontaneous recovery can thus be expected. In the relatively rare case of clinically significant respiratory paralysis, symptomatic treatment in the form of oxygen supplementation and/or mechanical ventilation should be employed until symptoms subside.
constitutive expression 1. The continuous transcription of a gene, as opposed to facultative expression, in which a gene is only transcribed as needed. A gene that is transcribed continuously is called a constitutive gene. 2. A gene whose expression depends only on the efficiency of its promoter in binding RNA polymerase, and not on any transcription factors or other regulatory elements which might promote or inhibit its transcription.
== Evolution == LCRs are very interesting from a micro and macro evolutionary perspective. They may be generated by DNA slippage, recombination and repair. Thus, they are linked to recombination hotspots and may even possibly facilitate cross-over. By originating from genetic instability, they may cause, at the DNA level, a certain region of the protein to expand or contract and even cause frame-shifts (phase-variants) that affect microbial pathogenicity or provide raw material for evolution. Most intriguingly, they may provide a window into the very early evolution of life. During early evolution, when only few amino acids were available and the primary genetic code was still expanding its repertoire, the first proteins were assumed to be short, repetitive and therefore, of low complexity. Thus, modern LCRs could represent primordial aspects of the evolution towards the protein world and may provide clues about the functions of the early proto-peptides. Most studies have focused on the evolution, functional and structural role of eukaryotic LCRs. However, a comprehensive study of prokaryotic LCRs from many diverse prokaryotic lineages provides a unique opportunity to understanding the origin, evolution and nature of these regions. Due to the high effective population size and short generation times of prokaryotes, the de novo emergence of a mildly or moderately deleterious amino acid repeat or LCR should quickly be filtered out by strong selective forces.
Sources: en.wikipedia.org
=== For injury to muscle or joint === For both muscle and joint injuries, it is common to alternate both cold and warm compresses to manage inflammation. Non-steroidal anti-inflammatory drugs and corticosteroids may also be used in conjunction.
A 2003 article said that South Koreans consume 18 kg (40 lbs) of kimchi per person annually. Many credit the Korean Miracle in part to the popularity of the dish. Adult Koreans eat from 50 grams (0.11 lb) to 200 grams (0.44 lb) of kimchi a day.
Detailed CIDRAP Smallpox overview Archived 6 May 2013 at the Wayback Machine Agent Fact Sheet: Smallpox, Center for Biosecurity Smallpox Images and Diagnosis Synopsis Archived 29 July 2008 at the Wayback Machine Virus Pathogen Database and Analysis Resource (ViPR): Poxviridae
Sources: en.wikipedia.org
A skeletal survey is useful to confirm the diagnosis of achondroplasia. The skull is large, with a narrow foramen magnum, and relatively small skull base. The vertebral bodies are short and flattened with relatively large intervertebral disk height, and there is congenitally narrowed spinal canal. The iliac wings are small and squared, with a narrow sciatic notch and horizontal acetabular roof. The tubular bones are short and thick with metaphyseal cupping and flaring and irregular growth plates. Fibular overgrowth is present. The hand is broad with short metacarpals and phalanges, and a trident configuration. The ribs are short with cupped anterior ends. If the radiographic features are not classic, a search for a different diagnosis should be entertained. Because of the extremely deformed bone structure, people with achondroplasia are often "double jointed". The diagnosis can be made by fetal ultrasound by progressive discordance between the short femur length and biparietal diameter by age. The trident hand configuration can be seen if the fingers are fully extended. Another common characteristic of the syndrome is thoracolumbar gibbus in infancy.
NpCl4 + 4 KC5H5 → Np(C5H5)4 + 4 KCl It is soluble in benzene and THF, and is less sensitive to oxygen and water than Pu(C5H5)3 and Am(C5H5)3. Other Np(IV) cyclopentadienyl compounds are known for many ligands: they have the general formula (C5H5)3NpL, where L represents a ligand. Neptunocene, Np(C8H8)2, was synthesized in 1970 by reacting neptunium(IV) chloride with K2(C8H8). It is isomorphous to uranocene and plutonocene, and they behave chemically identically: all three compounds are insensitive to water or dilute bases but are sensitive to air, reacting quickly to form oxides, and are only slightly soluble in benzene and toluene. Other known neptunium cyclooctatetraenyl derivatives include Np(RC8H7)2 (R = ethanol, butanol) and KNp(C8H8)·2THF, which is isostructural to the corresponding plutonium compound. In addition, neptunium hydrocarbyls have been prepared, and solvated triiodide complexes of neptunium are a precursor to many organoneptunium and inorganic neptunium compounds.
== Medical use == Exenatide is used to treat type 2 diabetes as an add-on to metformin, a biguanide, or a combination of metformin and a sulfonylurea, or thiazolidinediones such as pioglitazone. A 2011 Cochrane review showed a HbA1c reduction of 0.20% more with exenatide 2 mg compared to insulin glargine, exenatide 10 μg twice daily, sitagliptin and pioglitazone. Exenatide, lead to greater weight loss than glucagon-like peptide analogues. Due to shorter duration of studies, this review did not allow for long-term positive or negative effects to be assessed.
Bryza said that by the night of 7 August, he had called on the Georgian officials not to open fire on the invading Russians. Evgeny Gontmakher, member of the board of the Institute of Contemporary Development, said that he was told by employees of the Russian government that the major resolutions during the war were not made without Putin. Brigadier general Kārlis Krēsliņš said in an interview that Russian assertion that the war began on the night of 7 to 8 August was not true because six Georgian policemen were targeted by mine on 1 August and a Georgian village was bombarded on 2 August from the Ossetian-inhabited territory controlled by the Russian peacekeepers. Krēsliņš said that the Georgian servicemen noticed in 2008 that Ossetians continued to shoot whether did the Georgian troops return fire or not. Krēsliņš commented on the Russian readiness, "The [Russian] military was expecting only an order, and politicians organized the reason for such an order to be given." Krēsliņš said that Georgia noticed how the Russian troops were amassing on the border, but Georgia did not believe that Russia would attack, although Georgia was expecting that a Russian attack would probably begin in Abkhazia. He stated that Georgia was not prepared for the Russian invasion. Krēsliņš opined that Georgia could successfully defend against the Russian invasion due to its mountains, however, according to his information, Georgia ruled out this because Russia threatened to destroy the country's capital from the air. On 18 September 2008, the U.S.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.